

## Special Issue

# Unraveling New Horizon in Vascular Diseases: From Pathophysiology to Novel Therapeutic

### Message from the Guest Editors

Vascular pathologies represent one of the greatest challenges of our time. It is estimated that they will be one of the most prevalent pathologies and will cause the greatest mortality and loss of quality of life in the coming decades. All of this makes it necessary for clinical, biomedical, and technological research to focus on improving the understanding of vascular diseases in order to guarantee a real and effective translation of research. In this sense, our Special Issue aims to be a meeting point for a large number of professionals who have a vocation for understanding and translation in vascular pathologies as a whole. For this reason, we want to accommodate the three pillars of vascular pathology (arterial, venous, and lymphatic).

### Guest Editors

Prof. Dr. Miguel A. Ortega

Department of Medicine and Medical Specialties, IRYCYS, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain

Dr. Raul Diaz-Pedrero

1. Department of Surgery, Medical and Social Sciences, Faculty of Medicine and Health Sciences, University of Alcalá, Alcalá de Henares, Spain

2. Department of General and Digestive Surgery, University Hospital Príncipe de Asturias, Madrid, Spain

### Deadline for manuscript submissions

31 October 2025



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/222384](https://mdpi.com/si/222384)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).